Tuscany Study demonstrates safety and efficacy of tuspetinib plus standard of care venetoclax and azacitidine in patients with newly diagnosed AML ineligible for induction chemotherapy
Year: 2025
Type: conference-abstract
Source: Blood
Institutions: Yale University, University of California, Irvine, University of Miami, University of Alabama at Birmingham, UC Davis Comprehensive Cancer Center, University of California, Davis, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, USC Norris Comprehensive Cancer Center, Duke Cancer Institute, Aptose Biosciences (United States), The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417016033